877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
New Search    Reset Filters

C4H6, Drugs for benign prostatic hyperplasia

Categories

Alpha blockers (1)
Alpha-1 blockers (1)
Antihistamines (1)
Antihypertensive agents (1)
Cyclic compounds (1)
Drugs acting on the cardiovascular system (1)
Drugs acting on the genito-urinary system (1)
Drugs acting on the nervous system (1)
H1 receptor antagonists (1)
Pharmaceuticals (1)
Piperidines (1)
Psychoactive drugs (1)
Six-membered rings (1)
Urologicals (1)

Suppliers

AK Scientific (1)
Sigma Aldrich (1)

Pizotifen (15574-96-6)  
Sandomigran  ·  Pizotyline  ·  BC 105
Pizotifen (INN) or pizotyline (USAN), trade name Sandomigran, is a benzocycloheptene-based drug used as a medicine, primarily as a preventative to reduce the frequency of recurrent migraine headaches.
naftopidil (57149-07-2)  
1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective α1-adrenergic receptor antagonist or alpha blocker.
finasteride (98319-26-7)  
Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used mainly to treat an enlarged prostate or scalp hair loss in men. It can also be used to treat excessive hair growth in women and as a part of hormone therapy for transgender women. It is taken by mouth.
alfuzosin (81403-80-7)  
Urion  ·  UroXatral  ·  alfuzosin hydrochloride
Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the α1 blocker class. As an antagonist of the α1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).
BML-190 (2854-32-2)  
BML 190  ·  BML190  ·  indomethacin morpholinylamide
BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2 inverse agonist. BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity. The activity produced by this compound is disputed, with some sources referring to it as a CB2 agonist rather than an inverse agonist; this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.
bicalutamide (90357-06-5)  
Casodex  ·  4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide  ·  ICI 176334
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat advanced prostate cancer. Bicalutamide may also be used to treat excessive hair growth in women, as a component of feminizing hormone therapy for transgender women, to treat early puberty in boys, and to prevent overly long-lasting erections in men.
Thioproperazine (316-81-4)  
Majeptil  ·  thioproperazine mesylate
Thioproperazine, sold under the brand name Majeptil, is a typical antipsychotic of the phenothiazine group which is used as a tranquilizer, antiemetic, sedative, and in the treatment of schizophrenia.
doxazosin (74191-85-8)  
Cardura  ·  Doxazosin Mesylate  ·  Progandol Neo
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH). In March 2000, the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study stopped its arm of the trial looking at alpha blockers, because doxazosin was less effective than a simple diuretic, and because patients on doxazosin had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics. Pfizer, aware of the results before publication, launched a marketing campaign in early 2000, and sales were largely unaffected, despite the dangers highlighted by the study.